NCBiotech loan, NIH grants fuel development of Symberix GI drugs
DURHAM, N.C. – The challenge of developing new drugs to treat serious lower gastrointestinal disorders has got easier to digest for Symberix, a Durham biopharmaceutical company. The University of North Carolina at Chapel Hill spin-out is focused on early-stage development of a unique class of GI medicines. It was awarded a $250,000 Small Business Research Loan from the North Carolina Biotechnology Center, and has also received three National Institutes of Health Small Business Innovative Research grants totaling $2.9 million. Symberix also has entered into a research collaboration...
Read MoreUnder new chair, NC BIO to maintain push for more capital, workforce training
RESEARCH TRIANGLE PARK, N.C. – Mike McBrierty, the associate director of state public policy and government affairs for Biogen, will serve as the new chairman of NCBIO, the trade association of North Carolina’s bioscience industry. And he has a full slate of challenges ahead of him. “Mike has been a great contributor to NCBIO’s success throughout his terms on our Board,” said Sam Taylor, president of NCBIO in an interview. “His insights into the industry, political climate and public perceptions of North Carolina’s growing life science cluster will be a tremendous...
Read MoreFortune 500 Acquires Durham’s HyperBranch Medical for $220M
DURHAM, N.C. – Fortune 500 medical technology firm Stryker (NYSE: SYK), based in Kalamazoo, Michigan, has acquired Durham-based HyperBranch Medical Technology, Inc., for $220 million. HyperBranch CEO Jeff Clark has announced his retirement. However, Stryker will continue to manufacture Adherus AutoSpray Dural Sealant at the Durham facility, according to its spokesperson Jenny Braga. The Adherus AutoSpray Dural Sealant is used in brain surgery and is applied over stitches (sutures) for dura repair to prevent cerebrospinal fluid (CSF) from leaking out of the incision site as an...
Read MoreSEBIO One More Week – New Speakers Announced
Fundraising to make successful businesses in the early stage life sciences space is a daunting and complicated undertaking. Where to find the funds to advance these opportunities sometimes requires that an entrepreneur range far and wide. Fortunately, there are a number of ways for early stage life science companies to raise funds and with a new Early Stage panel, sources of funding in the southeastern early stage life sciences world will be discussed. The Metro Atlanta Chamber is sponsoring the Early Stage Investing: And We Mean Early Panel. This panel will be comprised of: Bob...
Read MoreTop 25 Biotech Companies of 2018
While several biopharma giants (including Amgen, Novartis, and Merck & Co.) reported third-quarter earnings that beat expectations in recent days, biotechs appear to have been caught up in the past month’s stock market swoon. As of October 26, according to Zacks Equity Research, the stock prices of companies in its “medical-biomedical and genetics” sector, which includes smaller as well as larger biotechs, had fallen 10.3% over the previous six months, compared with a 1.6% increase for the overall S&P 500. Even more sobering: three key exchange-traded funds (ETFs) consisting of...
Read More2 Weeks until #SEBIO2018 in Atlanta!
Join us at Loews Atlanta November 13-14 for the 20th Anniversary of the SEBIO Investor and Partnering Forum!! 2018 Home
Read More
Follow Us!